98%
921
2 minutes
20
Often in the planning phase of a clinical trial, a researcher will need to choose between a standard versus weighted log-rank test (LRT) for investigating right-censored survival data. While a standard LRT is optimal for analyzing evenly distributed but distinct survival events (proportional hazards), an appropriately weighted LRT test may be better suited for handling non-proportional, delayed treatment effects. The "a priori" misspecification of this alternative may result in a substantial loss of power when determining the effectiveness of an experimental drug. In this paper, the standard unweighted and inverse log-rank tests (iLRTs) are compared with the multiple weight, default Max-Combo procedure for analyzing differential late survival outcomes. Unlike combination LRTs that depend on the arbitrary selection of weights, the iLRT by definition is a single weight test and does not require implicit multiplicity correction. Empirically, both weighted methods have reasonable flexibility for assessing continuous survival curve differences from the onset of a study. However, the iLRT may be preferable for accommodating delayed separating survival curves, especially when one arm finishes first. Using standard large-sample methods, the power and sample size for the iLRT are easily estimated without resorting to complex and timely simulations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10743107 | PMC |
http://dx.doi.org/10.3390/ijerph20247164 | DOI Listing |
Neurol Res
September 2025
Henan Provincial People's Hospital, Department of Surgery of Spine and Spinal Cord, People's Hospital of Zhengzhou University, Zhengzhou, China.
Background: Immunotherapy holds significant yet underexplored potential for low-grade glioma (LGG) treatment. We therefore interrogated the role of Fanconi Anemia Complementation Group C (FANCC) as a novel immune checkpoint regulator given its spatial correlation with tumor microenvironments and clinical associations with immunosuppressive markers.
Objectives: FANCC is implicated in various tumor progressions; its role in LGG remains unexplored.
Sci Rep
August 2025
Department of Internal Medicine, Yonsei University College of Medicine, Yonsei-Ro 50-1, Seodaemun-Gu, Seoul, 03722, South Korea.
Besifovir dipivoxil maleate (BSV) has potent antiviral efficacy against chronic hepatitis B (CHB). This study investigated the efficacy of BSV in reducing hepatocellular carcinoma (HCC) development compared to other antiviral therapy (AVT) agents. We conducted a retrospective cohort study on treatment-naïve patients with CHB who initiated an AVT between 2017 and 2022 with BSV (n = 486), entecavir (ETV) (n = 852), tenofovir alafenamide (TAF) (n = 801), or tenofovir disoproxyl fumarate (TDF) (n = 750).
View Article and Find Full Text PDFMicrobiol Spectr
August 2025
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Infections from multidrug-resistant (MDR) bacteria lead to worse outcomes in immunocompromised patients. Eravacycline (ERV) is effective against MDR gram-negative and gram-positive bacteria, but its effects in immunocompromised populations remain unstudied. We aimed to evaluate clinical end points of immunocompromised patients receiving timely versus late ERV therapy.
View Article and Find Full Text PDFJ Thorac Oncol
August 2025
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Introduction: The goal of this study was to identify lung cancer biomarkers specific for African Americans (AA) by conducting a genome-wide analysis and understand the role of these biomarkers in overall survival.
Material And Methods: All cancer studied by the Cancer Genome Atlas (TCGA) were queried with TCGAbiolinks R package (RRID:SCR_017683) for mRNA expression, DNA methylation, and clinical data. Differential expression analysis was performed comparing mRNA expression between AA and Caucasians.
Front Pharmacol
July 2025
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Sepsis after cardiac surgery represents a severe perioperative complication with high incidence and mortality rates. While the cardioprotective benefits of β-blocker following cardiac surgery are widely recognized, their impact on sepsis development remains unclear. This study aims to investigate the association between early postoperative β-blocker use and the incidence of sepsis, as well as clinical outcomes, in patients undergoing cardiac surgery.
View Article and Find Full Text PDF